Recurrent skin infections associated with natalizumab treatment

Neurol Sci. 2023 Mar;44(3):1093-1095. doi: 10.1007/s10072-022-06481-2. Epub 2022 Nov 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunologic Factors / adverse effects
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis, Relapsing-Remitting* / complications
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Natalizumab / adverse effects

Substances

  • Natalizumab
  • Immunologic Factors